Evaluation of the clinical efficiency of antiviral therapy for recurrent genital herpes
Objective. To evaluate the efficacy of Valvir (valacyclovir) in the treatment of patients with recurrent genital herpes. Subjects and methods. The study covered 34patients aged from 18 to 35years, in whom the diagnosis of recurrent genital herpes was verified according to clinical and laboratory findings. The clinical efficiency of antiviral therapy was evaluated in the patients during 3 gynecology visits. Results. The findings suggest that disappearance of herpetic rashes and healing of focal lesions occurred with a high degree of statistical significance on day 4 of treatment. The area of affected foci with residual phenomena of herpetic rashes was decreased by 75% or more of the initial value at follow-up day 6. The duration of a recurrent genital herpes episode was reduced by 1.67 times. Conclusion. The episodic use of Valvir (valacyclovir) in patients with recurrent genital herpes can statistically significantly reduce the severity and duration of the current relapse and provide psychological support for the patients.